Form 497 TALCOTT RESOLUTION LIFE
Rule 497(e)
File Nos. 333-151805; 811-10559
TALCOTT RESOLUTION LIFE INSURANCE COMPANY
SEPARATE ACCOUNT ELEVEN
HV-6776 - Premier Innovations℠
HV-6777 - Hartford 403(b) Cornerstone Innovations
HV-6778 - Premier Innovations℠ (Series II)
Supplement dated June 10, 2026 to Prospectuses dated May 1, 2026
This supplement amends name information, effective August 1, 2026, for the PIMCO Total Return ESG Fund in the above-referenced product Prospectuses.
Accordingly, effective August 1, 2026, prior information for the PIMCO Total Return ESG Fund – Administrative Class in the “Appendix A – General Account Options and Underlying Funds” section of the Prospectuses will be updated as follows (all other information in the “Appendix A – General Account Options and Underlying Funds” section of the Prospectuses will remain unchanged):
UNDERLYING FUND TYPE | UNDERLYING FUND AND ADVISER/SUBADVISER | CURRENT EXPENSES | AVERAGE ANNUAL TOTAL RETURNS (as of December 31, 2025) | ||||||||||||||
1 YEAR | 5 YEARS (or since inception) | 10 YEARS (or since inception) | |||||||||||||||
US Fund Intermediate Core-Plus Bond | PIMCO Total Return ESG and Bond Fund - Administrative Class (Effective 8/1/2026, PIMCO Total Return ESG Fund is renamed PIMCO Total Return ESG and Bond Fund) | - | |||||||||||||||
Adviser: Pacific Investment Management Company, LLC | |||||||||||||||||
Subadviser: N/A | |||||||||||||||||
PLEASE RETAIN THIS SUPPLEMENT WITH YOUR PROSPECTUS
2026-PROSUPP-3
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Major new book charting the history of Crown and Parliament launched at Westminster Abbey
- John Ramirez Jr. Scholarship for First-Generation Students Opens 2026 Application Cycle to Support Undergraduate Trailblazers Nationwide
- Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share